GSK (LON:GSK) Hits New 52-Week Low – Here’s Why

Shares of GSK plc (LON:GSK) hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as GBX 1,380.50 and last traded at GBX 1,790.50, with a volume of 5175766 shares trading hands. The stock had previously closed at GBX 1,765.50.

Wall Street Analyst Weigh In

Several analysts have weighed in on GSK shares. Berenberg Bank upped their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Tuesday, September 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,975 price target on shares of GSK in a report on Tuesday, September 8th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 2,064.38.

GSK Price Performance

The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. The stock’s 50-day moving average price is GBX 1,870.41 and its 200-day moving average price is GBX 1,937.17. The company has a market capitalization of £71.75 billion, a price-to-earnings ratio of 15.20, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last released its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Equities research analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.

Insider Activity

In other news, insider Anne Beal bought 637 shares of the company’s stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds purchased 1,500 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were acquired at an average price of GBX 1,881 per share, with a total value of £28,215. Over the last 90 days, insiders have bought 2,144 shares of company stock worth $6,009,566. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.